Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Development of an opsonophagocytic killing assay for Group A Streptococcus

Group A Streptococcus (GAS) or Streptococcus pyogenes is responsible for an estimated 500,000 deaths worldwide each year.

Research

Rheumatic Heart Disease Worldwide: JACC Scientific Expert Panel

The authors present a variety of pressing clinical research questions on optimal RHD prevention and advanced care

Research

Topical antibiotics with steroids for chronic suppurative otitis media

To assess the effects of adding a topical steroid to topical antibiotics in the treatment of people with chronic suppurative otitis media

Research

Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation

Research

Prospective Assessment of Rhinovirus Symptoms and Species Recurrence in Children With and Without an Acute Wheezing Exacerbation

Time to reinfection with subsequent rhinovirus is not influenced by the species of the preceding rhinovirus

Research

Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder

Our study suggests that vagus nerve stimulation is a generally safe and effective adjunct treatment for CDKL5-associated epilepsy

Research

Evidence of functional cell-mediated immune responses to nontypeable Haemophilus influenzae in otitis-prone children

These data provide evidence that otitis-prone children do not have impaired functional cell mediated immunity

Research

Use of health services in the last year of life and cause of death in people with intellectual disability: a retrospective matched cohort study

People with intellectual disability were more likely to experience potentially preventable conditions at the end of their lives

Research

A phenotype centric benchmark of variant prioritisation tools

We hypothesised that the performance of variant prioriisation tools may vary by disease phenotype.